The annual reported number of malaria cases in 2018 was 4,198,029 with 341 deaths.

**Key**

- **Green**: Target achieved or on track
- **Yellow**: Progress but more effort required
- **Red**: Not on track
- **Gray**: No data
- **White**: Not applicable
Malaria

Global Fund Update
The Global Fund has announced that Rwanda will receive US$190.2 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2021-2023. The Global Fund has determined the total allocation amount based on Rwanda’s disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and previous disbursements. For Rwanda this is calculated at US$54.8 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Rwanda is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

Progress
Rwanda has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO and has completed the national insecticide resistance monitoring and management plan. The country has rolled out iCCM countrywide and has secured sufficient resources to distribute the required LLINs and RDTs in 2019. Rwanda has implemented an emergency response programme to address the upsurge in malaria cases. The country has a high rating in terms of public sector management systems (CPIA cluster D). Rwanda has enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Control Scorecard.

Impact
The annual reported number of malaria cases in 2018 was 4,198,029 with 341 deaths.

Key Challenges
● Reported malaria upsurges from 2015.
● Gaps in funding to support IRS scale-up.

Previous Key Recommended Actions
<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
<th>Progress</th>
<th>Comments - key activities/accomplishments since last quarterly report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vector Control</td>
<td>Address the falling vector control coverage</td>
<td>Q4 2019</td>
<td></td>
<td>3.3 million LLINs were delivered to the country in the last quarter</td>
</tr>
</tbody>
</table>

Rwanda has responded positively to the previous recommended action on the increase in cases observed since 2010 and continues to track progress as this action is implemented.

New Key Recommended Actions
<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact</td>
<td>Investigate and address the reasons for the increase in estimated malaria incidence between 2015 and 2018</td>
<td>Q4 2020</td>
</tr>
<tr>
<td>Address funding</td>
<td>Ensure the GF malaria funding application is submitted by Q3 2020 and ensure that resources are allocated to malaria control at a level that is sufficient to sustain the gains made in recent years</td>
<td>Q3 2020</td>
</tr>
</tbody>
</table>
RMNCAH and NTDs

Progress

Rwanda has achieved high coverage of tracer RMNCAH interventions, including exclusive breastfeeding, vitamin A, ARTs in the total population, DPT3 vaccination and skilled birth attendants. The country has significantly enhanced the tracking and accountability mechanisms with the development of the Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in Rwanda is measured using a composite index calculated from preventive chemotherapy coverage achieved for schistosomiasis, and soil transmitted helminths. Preventive chemotherapy coverage in Rwanda is high for soil transmitted helminths (99%), and slightly below WHO target for schistosomiasis (73%). Overall, the NTD preventive chemotherapy coverage index for Rwanda in 2018 is 85, which represents an increase compared with the 2017 index value (80).